• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer" [Canc. Lett. 459 (2019 Sep 10) 122-134].

作者信息

Liu Xu, Lu Ying, Xu Yunchao, Hou Sizhu, Huang Jinli, Wang Bo, Zhao Jinyao, Xia Shilin, Fan Shujun, Yu Xiaotang, Du Yue, Hou Li, Li Zhiyue, Ding Zijie, An Shuo, Huang Bo, Li Lianhong, Tang Jianwu, Ju Jingfang, Guan Hongwei, Song Bo

机构信息

Department of Pathology and Forensics, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.

Teaching Laboratory of Morphology, College of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.

出版信息

Cancer Lett. 2022 Jul 28;539:215695. doi: 10.1016/j.canlet.2022.215695. Epub 2022 Apr 29.

DOI:10.1016/j.canlet.2022.215695
PMID:35501203
Abstract
摘要

相似文献

1
Corrigendum to "Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer" [Canc. Lett. 459 (2019 Sep 10) 122-134].
Cancer Lett. 2022 Jul 28;539:215695. doi: 10.1016/j.canlet.2022.215695. Epub 2022 Apr 29.
2
Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer.外泌体转移的 miR-501 通过靶向胃癌中的 BLID 赋予阿霉素耐药性和致瘤性。
Cancer Lett. 2019 Sep 10;459:122-134. doi: 10.1016/j.canlet.2019.05.035. Epub 2019 Jun 5.
3
Exosomal Transfer of Macrophage-Derived miR-223 Confers Doxorubicin Resistance in Gastric Cancer.巨噬细胞来源的miR-223通过外泌体转移赋予胃癌多柔比星耐药性。
Onco Targets Ther. 2020 Nov 25;13:12169-12179. doi: 10.2147/OTT.S283542. eCollection 2020.
4
Corrigendum to "MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer", [Canc. Lett. 399 (2017) 53-63].
Cancer Lett. 2018 Apr 28;420:260. doi: 10.1016/j.canlet.2018.01.073. Epub 2018 Feb 21.
5
Corrigendum to "Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer"[Canc. Lett. 369 (2015) 58-66].《“人胃和胃癌中微小RNA组的鉴定揭示miR-133b/a-3p作为胃癌治疗靶点”的勘误》[《癌症快报》369 (2015) 58 - 66]
Cancer Lett. 2020 Dec 1;494:3-4. doi: 10.1016/j.canlet.2020.07.016. Epub 2020 Aug 19.
6
Corrigendum to "Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22" [Canc. Lett. 340 (1) (Oct 28, 2013) 72-81].《二烯丙基二硫化物通过上调miR-200b和miR-22经Wnt-1信号通路抑制人胃癌细胞增殖并诱导凋亡》的勘误 [《癌症快报》340 (1) (2013年10月28日) 72 - 81]
Cancer Lett. 2021 Feb 1;498:253. doi: 10.1016/j.canlet.2020.07.001. Epub 2020 Oct 5.
7
Corrigendum to "Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3" [Canc. Lett. 498 (2021) 130-141].《“长链非编码RNA LINC00657通过吸附miR-20a-5p和靶向RUNX3抑制宫颈癌发展”的勘误》[《癌症快报》498 (2021) 130 - 141]
Cancer Lett. 2021 Jun 28;508:73-75. doi: 10.1016/j.canlet.2021.03.005. Epub 2021 Mar 30.
8
Corrigendum to "B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells." [Canc. Lett. 375 (2016) 284-292].对“miR-27a上调B4GALT3促进人宫颈癌细胞的致癌活性”的勘误 [《癌症通讯》375 (2016) 284 - 292]。
Cancer Lett. 2020 Nov 28;493:16-18. doi: 10.1016/j.canlet.2020.07.019. Epub 2020 Aug 18.
9
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].《“DIO3，甲状腺激素失活酶，促进高级别浆液性卵巢癌的肿瘤发生和代谢重编程”的勘误》[《癌症通讯》501 224 - 233]
Cancer Lett. 2023 Jun 1;563:216196. doi: 10.1016/j.canlet.2023.216196. Epub 2023 Apr 25.
10
Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
Cancer Lett. 2021 Feb 1;498:243. doi: 10.1016/j.canlet.2020.10.027. Epub 2020 Oct 22.